Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 34 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence

19 Apr 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Ciani et al. analyzed international HTA practice of the actual considerations around using surrogate endpoint evidence for both pharmaceuticals and medical devices. Based on the analysis, the authors developed a web-based tool which helps health technology assessment agencies and payers assess the clinical and cost-effectiveness of healthcare technologies by considering surrogate endpoints and, thus, support the decision-making process.

Access the full-text article here.